m+Medelevator.RU
← Поиск публикаций
Analytical chemistry · 2026

Dichromatically Encoded DNA Nanodevice for High-Resolution Molecular Subtyping of Triple-Negative Breast Cancer.

СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Chen Zhao-Peng, Wang Lu-Xi, Zhou Xue-Mei, Luo Xin-Yu, Lei Yan-Mei, Zhuo Ying

Аннотация

Accurate cancer subtyping is essential for personalized medicine, yet existing diagnostic methods lack the multiplexing capability to decode complex biomarker signatures. Herein, we report a modular and dynamic DNA nanodevice, termed dichromatically routed hierarchically responsive DNA encoder (DRIVE), that enables the high-resolution molecular subtyping of triple-negative breast cancer (TNBC). Specifically, DRIVE integrates a tetrahedral DNA scaffold that is functionalized with two pairs of recognition and output modules responsive to apurinic/apyrimidinic endonuclease 1 (APE1) activity and specific microRNA (miRNA) expression. In the presence of APE1 and miRNA-21 (which are widely recognized as breast cancer biomarkers), the orthogonal recognition initiates a catalytic hairpin assembly (CHA) reaction that links a single DRIVE into a linear DNA nanostructure, thus significantly amplifying a monochromatic FAM signal. In TNBC subtypes that are characterized by the coexpression of APE1, miRNA-21, and miRNA-210, the cross-CHA makes a single DRIVE-form network DNA nanostructure, achieving the dichromatic FAM/Cy5 signal output. It is demonstrated that an approximately 4-fold enhancement in reaction kinetics of DRIVE is observed in comparison with that of individually dispersed probes. The dual-signal output enables a statistically significant differentiation of TNBC cells from other breast cancer subtypes. Together, this advance facilitates precise TNBC subtyping and provides great potential for accurate cancer diagnostics and personalized therapeutic strategies.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты